Status:
COMPLETED
Clinical Effects of Sivelestat Sodium on Improving ARDS in Patients With COVID-19
Lead Sponsor:
The First Hospital of Jilin University
Conditions:
ARDS Due to Disease Caused by SARS Co-V-2
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this retrospective multicentre cohort study is to examine the association between receipt of sivelestat and improvement in oxygenation among patients with acute respiratory distress syndro...
Detailed Description
We conducted a retrospective cohort study of patients admitted between December 2022 and May 2023 to general ICUs, respiratory ICUs and emergency ICUs across 14 hospitals in Jilin Province, China. We ...
Eligibility Criteria
Inclusion
- 1\) equal to or more than 18 years old, 2) had positive COVID-19 reverse transcriptase-polymerase chain reaction test results from upper airway swab, 3) fulfilled the Berlin definition of ARDS
Exclusion
- pregnant or lactating women, those with concomitant severe chronic respiratory diseases or end-stage malignant tumours, patients with duration of hospital stay or sivelestat administration less than 72 hours and patients for whom complete outcome data were not available.
Key Trial Info
Start Date :
December 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 31 2023
Estimated Enrollment :
387 Patients enrolled
Trial Details
Trial ID
NCT06218862
Start Date
December 1 2022
End Date
May 31 2023
Last Update
January 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yuting Li
Changchun, None Selected, China, 130021